Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finasteride for testosterone-induced erythrocytosis
NCT02548117Phase 3Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Feb 2016
- Primary completion
- Feb 2016
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of finasteride in Erythrocytosis, sponsored by Baylor College of Medicine. Primary endpoints: Serum hemoglobin parameters at 2 years and Serum hematocrit parameters at 2 years. Planned start Feb 2016; status: withdrawn.
02
Drugs
finasteride
03
Conditions
Erythrocytosis
Beyond the preview
Go deeper on NCT02548117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548117.